Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ELAHERE safely and effectively. See full prescribing information for ELAHERE. ELAHERE ® (mirvetuximab soravtansine-gynx) injection, for intravenous use . Initial U.S. Approval: 2022
Medication labelWhy this: Advisory · dailymed-prescription
ELAHERE® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test [see Dosage and Administration ( 2.1 )].
- generic_name
- mirvetuximab soravtansine
- product_names
- MIRVETUXIMAB SORAVTANSINE
- ndc
- 72903-853, 72903-853-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en